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Dual-tasking (DT) is a measure to detect impairments in people with multiple sclerosis (MS). We compared three DT methods
to determine whether cognitive (Montreal Cognitive Assessment (MoCA)) or physical disability (Expanded Disease Severity
Scale; EDSS) was related to DT performance. We recruited MS participants with low disability (<3 EDSS, 𝑛 = 13) and high
disability (≥3 EDSS, 𝑛 = 9) and matched controls (𝑛 = 13). Participants walked at self-selected (SS) speed on an instrumented
walkway (Protokinetics, Havertown, USA), followed by DT walks in randomized order: DT ABC (reciting every second letter of
the alphabet), DT 7 (serially subtracting 7’s from 100), andDT 3 (counting upwards, leaving out multiples and numbers that include
3). DT 7 resulted in the most consistent changes in performance. Both MS and control groups reduced velocity and cadence and
shortened step length during DT with no significant differences between groups. Control subjects widened stride width by about
1 cm while MS subjects (collapsed as one group) did not. MS subjects with higher disability significantly increased percentage time
in double support during DT compared to SS (𝐹 = 12.95, 𝑝 < 0.001). The change in DS was related to cognitive and not physical
disability (𝑟 = 0.54, 𝑝 < 0.05).
1. Introduction
Multiple sclerosis (MS) is an autoimmune neurodegenerative
disease, usually diagnosed between the ages of 20 and 40
[1]. People withMS (PwMS) experience unpredictable symp-
toms such as weakness, fatigue, and cognitive impairment
[2–5].
PwMS often describe feeling unsteady while walking
which is worsened when combined with another task such
as talking [6]. Challenges when completing two tasks at
once, also called dual-tasking or cognitive interference, divide
attention and can cause falls among people with central ner-
vous system impairments [7, 8].The ability to dual-task (DT)
is emerging as a potential outcome in rehabilitation and in
MS [9]. Although authors report that adding a cognitive task
to walking slows gait velocity in PwMS [10], it is not known
whether the impairment is peculiar to PwMS (compared to
controls) or whether gait velocity is the most important gait
parameter to evaluate [7, 11–13]. In one reviewofDT testing in
PwMS [7], five of the fourteen studies compared MS subjects
to controls [6, 14–17] and only two of these matched for
education, age, and gender [14, 17]. Considering that level
of education could impact cognitive performance, it would
be reasonable to match education level when recruiting
control subjects. Furthermore, it is not clear which method
of cognitive interference best detects impairments during DT
testing [7]. A frequently used method requires the subject to
serially subtract sevens beginning with 100 while walking [8,
18, 19]; however the technique has been criticized because it
was considered frustrating for subjects [18]. The relationship
of DT to disability is not clear [14, 16]. Some authors report
that changes in gait during DT correlated with cognitive and
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physical impairment [11] while others suggest it is related to
physical variables only [20].
We aimed tomeasure the impact ofDTon gait parameters
inMS subjects with low and higher disability levels compared
to controls and determine which of three DT methods con-
sistently affected gait. We also aimed to determine whether
cognitive or physical status was related to DT performance.
2. Methods
2.1. Participants. Following approval by the Health Research
Ethics Authority, participants with a neurologist-confirmed
diagnosis of MS according to the 2010 McDonald criteria
were recruited from the MS clinic or the rehabilitation hos-
pital outpatient service [21]. They were included if they were
older than 18 years of age, relapse-free in the previous three
months, and able to provide consent. They were excluded if
they had musculoskeletal impediments to walking. The most
recent Expanded Disease Severity Scale (EDSS) score was
extracted from the health record. Participants with EDSS <
3 were assigned to the low disability group and those scoring
EDSS ≥ 3 to the high disability group. To create a comparison
group, we recruited a convenience sample of age (±3 years),
gender, and education (±3 years) matched subjects without
MS or any musculoskeletal or neurological conditions.
We calculated sample size based on mean and SD of
two previous studies examining DT in subjects with MS and
healthy controls [15, 22]. Velocity at self-selected (SS) walking
was used for the calculation [15, 22]. With significance set at
𝑝 < 0.05 and power at 0.8 and depending on which study was
considered, the sample size was estimated at 6 or 12 per group.
We aimed to recruit 10 subjects in each group (low disability,
high disability, and controls).
2.2. Protocol. Subjects attended one testing session. After
obtaining consent and collecting demographic information,
participants completed the Montreal Cognitive Assessment
(MoCA; scored out of 30) which has been tested in MS
patients [23]. Participants walked at their comfortable walk-
ing speed (SS) twice along an instrumented walkway (1.2
× 4.3m, PKMAS, Protokinetics Inc., Havertown, PA). They
then completed three DT conditions in random order with
directions provided using a standard script, walking twice
across the walkway during each method. The three DT
methods included reciting alternate letters of the alphabet
beginning with B (DT ABC), counting backwards from 100
by subtracting 7’s (DT 7), or reciting numbers beginning with
the number 1 while excluding those which included the digit
3 or numbers which were multiples of 3 (DT 3). DT ABC had
been previously tested in MS [10] and DT 7 in Alzheimer’s
disease [18]. The DT 3 was a new method devised to be a
simple nonrhythmical task.
2.3. Gait Variables. Forces and location of forces using an
x-y-z coordinate system were calculated by the walkway
software. Variables included average stride length, average
stride width, average percentage of time in double support,
average velocity, and average cadence [10, 11, 14]. Stride
length (cm) was the distance from the heel of one foot to
the subsequent heel strike of the same foot. Stride width
(cm) was the distance between a line connecting the two
ipsilateral foot heel contacts and the contralateral foot heel
contact perpendicular to the stride. Percentage time in double
support (DS) was the sum of all periods of time when both
feet were in contact with the ground, as percentage of total
gait cycle time. Velocity was calculated by dividing the sum
of all the stride length measurements by the sum of all
stride time measurements, presented in cm/s. Lastly, cadence
(steps/min) was the total number of footfalls minus one,
dividing by the ambulation time and multiplying the result
by 60. Since we expected that subjects could also exhibit gait
variability during DT, we also extracted the coefficient of
variability (CV) for each variable listed above.
2.4. Data Analysis. After removing incomplete footfalls, data
was exported and analyzed in SPSSv21. We calculated dual-
task cost (DTC) using the previously published equation,
where SS was self-selected pace output and DT was a dual-
task output for a specific variable [10–12, 15]:
DTC = SS − DT
SS
× 100%. (1)
We used descriptive statistics and 𝑡-tests to compare
demographic characteristics between groups and for the
categorical variables chi-square. Effect of group (MS subjects
or controls), condition (SS and DT conditions), and group ×
condition interaction was compared using two-way repeated
measures ANOVA. Significance was set at 𝑝 < 0.05 and if
there was a significant effect of group or condition, post hoc
comparisons were completed (Bonferroni).We examined the
correlations between DTC and the MoCA score (cognition)
or EDSS (MS-related disability) using bivariate correlations
(Pearson coefficient, with significance set to 𝑝 < 0.05).
3. Results
3.1. Participants. We recruited 11 MS participants with low
disability (<3 EDSS; 7 females, 4 males), 9 MS participants
with high disability (≥3 EDSS; 6 females, 3 males), and 13
controls (8 females, 5 males). Of the participants with MS,
15 were diagnosed with relapsing-remitting (RRMS) and five
as secondary progressive MS. Some control subjects matched
more than one participantwithMS.Therewere no differences
in age (𝐹 = 0.76, 𝑝 = 0.48), gender (𝐹 = 0.03, 𝑝 = 0.97), or
education (𝐹 = 0.11, 𝑝 = 0.90) between groups (Table 1).
Since the order of the dual-task conditions was randomly
assigned, we tested to determine if there was an effect of order
on all the reported variables. Of the five gait variables and four
conditions (SS and 3DT conditions), only velocity duringDT
7 task was affected by order (𝐹 = 2.64, 𝑝 = 0.05). We applied
a more stringent significance value of 𝑝 < 0.01 to account for
this effect during analysis of velocity.
3.2. Effects of DT in MS Participants and Controls. As
expected, for stride length, velocity, and cadence, there was
a significant decrement in performance in both MS subjects
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Table 1: Demographic and clinical characteristics of the study
population.
Characteristics
Low
disability
(𝑛 = 11)
High disability
(𝑛 = 9)
Controls
(𝑛 = 13)
Gender 7 females4 males
6 females
3 males
8 females
5 males
Age (years) 42.64 ± 11.16 48.44 ± 8.55 45.92 ± 11.31
Post-secondary
education
(years)
3.36 ± 2.11 3.33 ± 1.58 3.62 ± 0.96
Years with MS 9.73 ± 5.82 13.67 ± 8.28 N/A
EDSS score 1.59 ± 1.02Range (0–2.5)
4.39 ± 1.39
Range (3.0–6.5) N/A
EDSS: Expanded Disease Severity Scale. Values mean ± SD.
and controls during DT (Table 2). All groups exhibited
similar shortening of stride length by about 11–19 cm with
significant effect of condition (𝐹 = 20.28, 𝑝 < 0.0001) but
no effect of group (𝐹 = 1.55, 𝑝 = 0.23) or group × condition
interaction (𝐹 = 1.13, 𝑝 = 0.35). Post hoc analysis showed
that all DT methods in the MS groups resulted in reduced
stride length compared to SS. In the control group, only DT
7 resulted in decreased stride length.
With the addition of DT, walking velocity decreased by
about 21–46 cm/s with a significant effect of condition (𝐹 =
42.04, 𝑝 < 0.0001) but no effect of group (𝐹 = 1.05, 𝑝 = 0.36)
or group × condition (𝐹 = 1.90, 𝑝 = 0.09). Post hoc analysis
showed that all subject groups exhibited reduced velocity
duringDT compared to SSwith no difference between theDT
methods. Similar to velocity effects, cadence also decreased
by about 13–31 steps/min during DT compared to SS with a
significant effect of condition (𝐹 = 27.93, 𝑝 < 0.0001) but
no effect of group (𝐹 = 1.04, 𝑝 = 0.37) or group × condition
(𝐹 = 2.88, 𝑝 = 0.07).
Two variables, DS and stride width, were important
in distinguishing between subject groups. With respect to
DS, we were able to distinguish the MS participants with
higher disability from controls. Repeated measures ANOVA
revealed a significant effect of condition (𝐹 = 13.99, 𝑝 <
0.0001) and group (𝐹 = 4.14, 𝑝 = 0.03) but not group
× condition (𝐹 = 0.60, 𝑝 = 0.73). As expected, at SS
speed, the high disability group spent significantly longer
time in DS (35.1% SD9.8) compared to the low disability
group (28.6% SD2.8) and controls (27.3% SD2.6).MS subjects
in high and low disability groups increased time in DS during
DT compared to SS, adding about an additional 4% (𝐹 =
11.72, 𝑝 < 0.0001; 𝐹 = 5.36, 𝑝 < 0.01), while control
subjects did not (𝐹 = 2.45, 𝑝 = 0.08). In terms of stride
width, there was no significant effect of condition (𝐹 = 1.88,
𝑝 = 0.14), group (𝐹 = 2.26, 𝑝 = 0.12), or condition ×
group (𝐹 = 1.31, 𝑝 = 0.26). However, when comparing the
combined MS groups with controls, there was an effect of
condition approaching significance (𝐹 = 2.61, 𝑝 = 0.06) and
no effect of group (𝐹 = 0.00, 𝑝 = 0.98) and condition × group
(𝐹 = 2.43, 𝑝 = 0.07). Control subjects widened their stride
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Figure 1: Dual-task cost of double support is related to cognition:
in subjects with multiple sclerosis, lower cognitive score, measured
by the Montreal Cognitive Assessment, is associated with greater
dual-task cost of double support (𝑟 = 0.54, 𝑝 < 0.05). DT 7, serially
subtracting 7’s from 100, MoCA, Montreal Cognitive Assessment.
width on average 1 cm with the addition of a DT whereas
MS subjects did not demonstrate this behavior (Table 2). In
fact, in some DT conditions there was a trend, although not
significant, of narrowed stride width in MS subjects.
We calculated CV for each gait variable (stride length,
stride width, DS, and stride time, resp.). There was no effect
of group, condition, or group × condition interaction (data
not shown).
3.3. Comparing Methods to Detect the Impact of DT. We
combined the low and high disability MS groups to compare
DTC across the three DT methods (Table 3). DT 7 condition
produced the largest and most consistent DTC in stride
length and DS in the MS group. In terms of stride length and
DS, there was an effect of condition (𝐹 = 4.81, 𝑝 = 0.01;
𝐹 = 4.08, 𝑝 = 0.02), but not group (𝐹 = 1.81, 𝑝 = 0.18;
𝐹 = 0.69, 𝑝 = 0.51) or group × condition (𝐹 = 0.33,
𝑝 = 0.86; 𝐹 = 0.75, 𝑝 = 0.56). There was no significant
effect of group, condition, or group× condition inDTCof gait
variables: velocity, cadence, or CV (data not shown). When
examining stride width, although there was no significance of
group (𝐹 = 3.13, 𝑝 = 0.06), condition (𝐹 = 1.46, 𝑝 = 0.24),
or group × condition (𝐹 = 0.65, 𝑝 = 0.63), the group effect
approached significance. Post hoc analysis showed that the
DTC of stride width in MS subjects was less than controls
(𝑝 < 0.05; all DT methods; Table 3).
3.4. Relationship between DT Performance and Cognitive and
Physical Disability. Firstly, there was no correlation between
cognitive score measured using MoCA and any DTC in
control subjects (𝑝 > 0.05; data not shown). In MS subjects,
cognitive score was not related to gait variables at SS speed
(𝑝 > 0.05) or to EDSS (𝑝 > 0.05; data not shown).
We found that neither EDSS nor SS walking correlated
with DTC (𝑝 > 0.05) suggesting that people with greater
physical impairment do not exhibit greater cost of DT.
Importantly, we found that of the gait variables examined
DTC of DS was the only variable correlated with cognitive
score (𝑟 = 0.54, 𝑝 < 0.05). MS subjects with lower cognitive
scores (out of 30) had greater DTC of DS (Figure 1).
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Table 3: Comparing dual-task cost (DTC) of three DT methods.
MS Controls
DT ABC DT 7 DT 3 DT ABC DT 7 DT 3
Stride length DTC 8.88 ± 7.45b 12.69 ± 9.71 8.74 ± 7.61b 4.38 ± 10.48 6.42 ± 10.00 5.12 ± 9.95
Stride width DTC 5.83 ± 26.32∗ −0.34 ± 26.33∗ 6.90 ± 33.08∗ −19.18 ± 42.53 −32.87 ± 50.61 −24.97 ± 50.66
Double support DTC −11.70 ± 13.27b −18.89 ± 21.79 −11.89 ± 15.60 −6.93 ± 15.31 −10.86 ± 25.71 −9.35 ± 15.19
Velocity DTC 30.16 ± 20.12 32.18 ± 21.78 31.12 ± 16.04 20.66 ± 21.70 23.98 ± 26.58 20.33 ± 28.14
Cadence DTC 22.31 ± 18.49 23.48 ± 17.53 23.16 ± 14.66 17.41 ± 17.97 19.34 ± 21.12 11.36 ± 21.21
∗Different from control group (𝑝 < 0.05); bdifferent from DT 7 in the same group; DT ABC: dual-task while reciting alternate letters of alphabet; DT 7: dual-
task while serially subtracting 7’s from 100; DT 3: dual-task while counting, leaving out multiples and numbers including 3; DTC: dual-task cost; values are
mean ± standard deviation.
4. Discussion
Finding sensitive and reliable outcome measures that detect
clinically important impairments in MS is paramount for
future clinical rehabilitation trials. Dual-tasking is one such
potential outcome measure. Our objective was to determine
which DT method most consistently detected impairment in
MS subjects and which gait variables were most important
to consider. Although Leone and group have stated that “it
still remains unknown which task has the most detrimental
impact on DT performance” [7], we found that counting
backwards by sevens (DT 7) produced the most consistent
DTC in both MS subjects and controls. As suggested by
Kalron and group, it is important that the tasks employed
during DT testing are of adequate challenge in order to detect
effects [16]. To our knowledge this is the first comparison
of DT methods in MS subjects of varying disability and
age, gender, and education matched control subjects. Our
findings coincide with those of Muir et al. who showed that,
in people with mild cognitive impairment and Alzheimer’s
disease, DT 7 while frustrating was effective in identifying
DT impairments [18]. Although reciting alternate letters of
the alphabet (DT ABC) has been examined in PwMS [10],
we observed that the method was rhythmical, sometimes
stabilizing rather than challenging walking.
We also sought to determine which gait parameter would
be uniquely altered in MS subjects. Although other studies
have focused on DTC of gait velocity [6, 10–12, 14–17, 22,
24], we found that velocity, stride length, and cadence were
reduced in a similarmanner amongMS subjects and controls.
Furthermore, the DTC of these variables were not altered by
level of disability (EDSS score ≥ or <3) suggesting that DTC
of velocity, stride length, and cadence are likely “blunt” tools
to detect change as a result of intervention or the course of the
disease. Although Sosnoff et al. reported differences in DTC
of velocity betweendisability levels, the study divided subjects
into three disability classifications and found differences
only between the mild and severely affected groups [12].
Our comparison groups were more alike in disability level,
suggesting that DTC of velocity did not detect smaller differ-
ences in EDSS scores. In terms of other gait variables, since
other researchers have identified gait variability as a potential
indicator of impairment inDT, we examined the variability of
gait by calculating the coefficient of variability and found no
effect ofDT in any groups. Similarly,Hamilton and colleagues
found no significant differences in DS variability betweenMS
subjects and control groups [15].
Percentage time in DS, at SS pace, was a uniquely altered
variable in some MS subjects, with greater DS time in high
disability MS subjects compared to controls. We did not find
a significant difference between the low disability group and
controls. In contrast, Kalron and colleagues were able to
distinguish patients with clinically isolated syndrome (CIS)
from controls [16] which may have been related to the fact
that subjects had recent onset of neurological symptoms
(<90 days). We also show that DS increases significantly in
MS subjects during DT but not in controls. Our findings
conflict with those of Motl et al. who showed that DS was
not significantly altered by DT in a sample of 82 people with
RRMS [11]. Nogueira and colleagues also reported that DS
increased during DT in both MS subjects and controls [24].
The discrepancies may be related to the fact that we tested
subjects with greater variability in walking disability.
In our study, stride width and DTC of stride width
emerged as unique indicators of MS-related impairment. As
reported by others, we found that, at SS speed, as disability
level increased, the base of support increased [12]. When col-
lapsing the MS groups, we report a paradoxical phenomenon
in which stride width is either narrowed or unaltered during
DT in MS subjects and widened in control subjects which
suggests a maladaptive balance response in MS subjects. Our
findings concur with those of Nogueira et al. who reported
that, in people with MS, step width (calculated in a similar
way to stride width) decreases by about 1 cm during a dual
task whereas it increases the same amount in controls [24].
Several authors have shown that stride/step width is not
altered during DTC in MS; however previous studies have
tested less severely affected subjects [12, 16]. Gunn et al.
observed that 70% of MS patients experienced falls over
a three-month period [13]. Older people who experienced
lateral falls have narrower step width compared to other
direction fallers [25]. Our findings suggest that stride width
may be a reasonable measure of DTC; however this should be
confirmed with a larger study cohort.
We also aimed to determine the relationship between
DTC and cognitive and physical status. Confirming the work
of others [9, 10, 14], we found that although walking at
SS pace is related to physical disability (EDSS), the cost
of DT walking is related to cognition. We found that only
DTC of DS was significantly correlated with cognitive score
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(measured by MoCA) but not EDSS or walking at SS pace. In
MS subjects, greater cognitive impairment is associated with
greater increases in DS during DT. Contrary to our findings,
others have reported correlations between DTC and EDSS
scores [11, 14, 20]. The discrepancies may be related to the
degree of cognitive challenge employed during the DT in
these studies which were relatively simple word generation
tasks or counting forwards or backwards.
Although our results provide new understanding of the
use of DT to detect cognitive interference in MS, there
are some limitations. We chose three tasks, all requiring
good language ability. Future studies should evaluate other
methods that employ a nonlanguage task such as a visual cue.
We did not examine the cost of DT on the cognitive task.
Understanding the DTC on cognitive performance is an area
that requires further exploration. We tested a group of MS
patients with a range of walking ability; however we cannot
assume that these findings apply to all people with MS.
5. Conclusion
Our findings indicate that DT 7 (serially subtracting 7’s from
100) is the most reliable cognitive task to detect DTC of
the gait variables assessed. Increased percentage time in DS
distinguished the high disability MS group from controls.
Control subjects widened stride width when challenged by
a DT whereas MS subjects (with subgroups collapsed) para-
doxically did not. Finally, physical disability (EDSS) in MS
subjects was related to gait parameters at SS pace, but DTC
was related to cognitive performance (MoCA), indicating
that challenges for many MS patients to optimally multitask
may be dependent upon their cognitive, not physical, disabil-
ity.
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